JPRN-UMIN000016355已完成未知
Safety and efficacy of Daclatasvir and Asunaprevir combination therapy for hemodialyzed patients with chronic hepatitis C - Daclatasvir and Asunaprevir therapy for hemodialyzed ptatients
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1 patients with heart failure 2 patients with decompensated cirrhosis 3 patients with allergic to NS5A inhibitor or HCV PI inhibitor 4 patients with HCC or other malignant disease
研究者
相似试验
已完成
不适用
Safety and efficacy of Daclatasvir and Asunaprevir combination therapy for hemodialyzed patients with genotype 1 chronic hepatitis C infectiohemodialyzed patients with genotype 1 chronic hepatitis C infectionJPRN-UMIN000024227others130
已完成
不适用
Efficacy and safety of daclatasvir and asunaprevir in chronic hepatitis C patients with hemodialysisChronic hepatitis C with hemodialysisJPRN-UMIN000016181shonan kamakura general hospital30
已完成
不适用
Efficacy and safety of daclatasvir and asunaprevir in patients with chronic hepatitis CPatients with chronic hepatitis C virus infectionJPRN-UMIN000015247Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology350
Unknown
4 期
Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis CHepatitis C, ChronicNCT02639585Pusan National University Hospital32
已完成
3 期
A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects with Chronic Hepatitis C Genotype 1b Infection.;+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 13-Mar-12)Chronic Hepatitis C infection or Chronic HCV10047438Hepatitis CNL-OMON37621Bristol-Myers Squibb18